The purpose of this paper is to review and summarize the current knowledge on conservative management of localized prostate cancer. Deferring treatment for low-grade, clinically localized prostate cancer is an acceptable treatment option for patients with a life expectancy of 10±15 y or less. The outcome of available studies on deferred treatment in selected series cannot be compared with the outcome in register studies where the patients have been managed with noncurative intent, nor can it be directly compared with the outcome of selected series on other treatments. The outcome of different treatments for localized prostate cancer can only be compared in randomized studies.
Introduction
There is a continuing and considerable controversy in the urological world over the management of patients with clinically localized prostate cancer. The options range from deferring treatment to radical surgery. This controversy is illustrated by the fact that in Denmark only a few radical prostatectomies have been performed 1 while the number of such procedures in the United States increased dramatically from approximately 2500 in 1984 to a peak of more than 34 000 in 1992 among Medicare bene®ci-aries 2 and additionally many thousands more procedures outside this system. Despite the enormous difference in aggressiveness in the general attitude towards searching for and treating prostate cancer, the mean age adjusted incidence of death from prostate cancer in Denmark and the United States from 1990±1993 was almost similar, 19.5 and 17.5a100 000, respectively. 3 Moreover, the differences in outcome have been small in nonrandomized comparisons of aggressive local treatments such as radical prostatectomy or irradiation and deferred treatment.
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The bene®t of aggressive treatment with observation up to 10 years after the diagnosis has therefore been questioned. 7 There are to this date no randomized treatment trials with reliable outcome data in this ®eld. The only randomized comparison of deferred treatment and radical prostatectomy showed no difference in overall survival after more than 20 y of follow-up. 8 The outcome of this study must, however, be interpreted with care because of a small sample size and¯aws in its conduct. Recently, data have been presented suggesting that the longer a man lives with his prostate cancer the greater the risk that he dies of the tumor. 9 These data have challenged the concept of deferring treatment for men with longer life expectancy, but they appear not to be comparable with earlier data.
De®nitions
Confusion exists over the nomenclature with respect to conservative management of prostate cancer. To clarify this issue conservative management can be sub-divided as follows: (1) deferred treatment (watchful waiting) that is no initial treatment followed by therapy which is usually, but not necessarily, endocrine treatment if and when symptoms occur, and (2) treatment with noncurative intent that is usually early or late endocrine treatment. Deferred treatment is normally applied to selected groups of patients with de®ned tumor categories and tumor grades. Treatment with noncurative intent has usually been evaluated in population-based series of patients often identi®ed in various registries where for example grade and stage have not been possible to assess. The latter studies have invariably been retrospective, while some studies on deferred treatment have been prospective with formal protocols (see below).
Deferred treatment has been an established management for localized prostate cancer in Scandinavia since the early 1970s. The rationale of this management is that the course of the early prostate cancer is often protracted and, since the age of the men with prostate cancer is usually high at diagnosis, the competing mortality is substantial. Therefore, many men die with their prostate cancer rather than from it, irrespective of treatment. Moreover, deferring treatment will also ideally lessen the impact of treatment-related symptoms on the patients' quality of life.
Endpoints
Survival and quality of life of the patients are the endpoints that have been recommended for treatment studies of localized prostate cancer. 10 However, since many patients with prostate cancer die of other causes than prostate cancer, overall survival may be too blunt an instrument to detect differences in outcome in treatment studies. Moreover, since the age of the patients is often related to the treatment 4 resulting in different risks of competing mortality, overall mortality may be less appropriate to evaluate the survival outcome in studies on localized prostate cancer. Instead disease-speci®c survival may be used since this only takes the mortality from the studied disease into account because the competing mortality is censored in the analysis. However, in the case of a deadly disease with a slow course, such as localized prostate cancer, the competing mortality may the true mortality from the disease mask. This will be important when comparing groups with large differences in mean age. Also, disease-speci®c survival precludes that the cause of death is determined in each case. The precision in death certi®cates with respect to the correctness of the cause of death may vary and if cause of death is determined from case records it becomes investigator dependant. These uncertainties with respect to determining a correct cause of death will always hamper disease-speci®c survival as an endpoint. Disease-free survival is also commonly used and it is a combination of two endpoints, the recurrence or persistence of the disease and the survival of the patient. Since disease recurrence or persistence is often dif®cult to de®ne clinically and varying de®nitions are used, this endpoint cannot be used in comparisons between nonrandomized groups. 11 Relative survival, that is the quotient between the survival for an actually observed group of patients and the expected survival of a matched group of individuals from the general population is often used to illustrate an excess mortality associated disease. This excess mortality can be due to mortality from the disease, treatment or other disease related factors. The selection of the matched group is crucial for the parameter. This needs to done for each observed year since the mortality from the studied disease may gradually change the age distribution in the compared groups. 12 The difference in mean age that occurs has to be corrected continuously to account for differences in mortality from causes other than the studied disease. Relative survival is best suited for use in large series which often means registry studies. Ideally, the relative survival will approximate the disease-speci®c survival without a knowledge of the exact cause of death of each individual.
In many papers the survival of an observed group is compared with an initially age-matched survival from the general population in graphical form. Very often the survival in the observed group is equal or close to that of the`matched' sample which in turn is taken frequently as an indication of ef®cacy of the treatment. Such comparisons are, however, bound to be spurious because of the above described difference in intercurrent mortality which will occur and also because of selection of generally healthier individuals to the treatment group, for example as in the case of radical prostatectomy.
There is a clear difference in the scienti®c importance of these survival endpoints and the importance that they have to the patients. Disease-speci®c survival may be the compromise that is scienti®cally most practicable. It answers the question: If I do not die of other disease before for example 10 y what is my chance of still being alive at that point of time? This may, however, not be the most relevant question for the patient. The patient is probably more likely to ask what his chance of being alive at 10 y is which is answered by the overall survival.
Obviously, symptoms inferred by the prostate cancer and its treatment and the impact on the well-being and the quality of life is very important for the patient. Unfortunately, we have little data on which we can base our answers to the patients in this respect. Therefore, treatment studies on localized prostate cancer should ideally include overall survival, disease-speci®c survival and quality of life as outcome measures.
Outcome of conservative treatment for localized prostate cancer
Survival

Deferred treatment in selected series
The outcomes of published series of patients with palpable clinically localized prostate cancer managed with deferred treatment are displayed in Table 1 . Overall survival ranges from 34±55% and 32±43% at 10 and 15 y, respectively (Table 1) . Disease-speci®c survival at 10 y ranges from 72±87% with the higher values in the larger studies (Table 1) . Only one published study reports 15 y disease-speci®c survival being 81%. 13 In the Stockholm series 14 the projected disease-speci®c survival at 15 y was lower than in the o È rebro series. 13 Quality of life has not been formally investigated in any of these studies. However, in the Stockholm series the chance of still being untreated 10 y after the diagnosis was just over 40% which could mean less morbidity from treatment and possibly an improved quality of life in this respect for the patients. 14 The data on morbidity from prostate cancer in the studies are too few to permit any conclusions. To date, no series with patients with nonpalpable tumors found by prostate speci®c antigen with long-term follow-up have been published.
All these series are selected in various ways, either on formal grounds or by chance. For example in the series by Johansson et al. 13 only patients with well differentiated tumors were included during the ®rst 2 y. Thereafter patients with tumors of all grades were included. In the series from Stockholm no patients with poorly differentiated tumors were included. 15 The method of inclusion and the time period during which the inclusion took place also varies. One extreme in this respect is the series from New York which was retrospective and comprised 75 patients out of possibly many hundreds or even thousands with prostate cancer admitted to the Memorial Sloan-Kettering Cancer Center from 1949±1986. 16 The other extreme is the series from O È rebro in Sweden where the department of urology at the regional hospital sees all new patients with urological malignancies in the O È rebro County. 13 This series is therefore population-based with a de®ned study base, out of which patients meeting speci®c formal criteria were selected to a prospective surveillance protocol. The selection in the O È rebro series is therefore possible to assess with great certainty and the patients not included in the surveillance group have also been accounted for. 13 The series was gathered during a relatively short time as was the prospective series from Stockholm. 15 Both these series are still being followed and so far it has been possible to follow all included patients. The series reported on by George 17 was more heterogeneous with respect to stage and grade than the two Swedish series. Data from this series has only been published once with an approximate median follow-up of only 5 y.
It is evident that all these major series on deferred treatment of localized prostate cancer are subject to selection in various ways, which may or may not in¯u-ence the outcome. The series are also followed up in different ways and for varying times. Bias, especially from selection which possibly results in an uneven distribution of prognostic factors, makes it dif®cult to compare these series with each other and yet even more dif®cult to compare them with single series on other treatments.
Pooled analysis of series on deferred treatment
Three of the above-mentioned single series on deferred treatment together with three other and smaller series, were included in a pooled analysis. 18 These six series originate from four different countries, Sweden, Israel, United Kingdom and the United States. Altogether, data from 828 patients were available and 820 patients were evaluable both with respect to tumor grade and tumor stage. The patients had clinically localized prostate cancer of all grades. Primary data from all patients were included in a new survival analysis with life-table technique. A quarter of the patients had been observed 11 y or more. The different series were ®rst checked with respect to heterogeneity regarding survival outcome. The series from Israel had a signi®cantly poorer outcome than the others, but, since this would not bias the outcome to the better, it was included in the analysis. The disease-speci®c survival at 10 y was 87% for patients with grade 1 and grade 2 tumors and 34% for patients with grade 3 disease. The metastasisfree survival at 10 y for patients with grade 1 disease was 81%, and for the patients with grade 2 disease it was 58%. The lower metastasis-free survival for the latter group may result in an increased mortality from prostate cancer in this group beyond 10 y of followup.
The value of this pooled analysis can be debated since as mentioned above, the patients in the included series, were selected in various ways. However, no major heterogeneity with respect to survival favouring any of the studies was found. On the contrary, to be conservative in the analysis the study showing a poorer outcome than the other ®ve was included in the analysis. However, because of selection and other differences from series on other treatments, direct comparisons must be made cautiously. On the other hand the data in the pooled analysis represents the largest set of data on survival outcome for deferred treatment that we have. 
Deferred treatment in randomized trials
To this date there are only two published randomized trials on localized prostate cancer with deferred treatment as one treatment arm. In the United States the VACURG group compared deferred treatment versus radical prostatectomy and the overall survival at 15 y was 32% in patients with VACURG stage I and II tumors (nonpalpable tumors found at surgery for apparently benign prostatic hyperplasia and palpable tumors clinically con®ned to the prostate gland). 19 There was no difference in overall survival after more than 20 y observation. 8 In Sweden, Lundgren et al. 20 compared two different endocrine treatments with deferred treatment in patients with T0-T3 tumors (UICC 1978). They found in the deferred group an overall and disease-speci®c survival at 10 y of 49% and 74%, respectively. Both endocrine treatments had a survival outcome that was signi®cantly better than that in the deferred group.
Both these studies can be criticized for methodological aws in their conduct andaor small sample sizes and the results must therefore be interpreted with great caution.
Compilations of data from single treatment series
Because we do not have any reliable controlled comparative outcome data regarding survival after various therapies for localized prostate cancer, several authors have done literature reviews and compiled the available outcome data to increase the precision of the outcome estimates. Three such studies have been published recently. 4±6 Wasson et al. 6 and Adolfsson et al. 4 calculated the annual incidence of death from prostate cancer after deferred treatment to be 0.9% and 1.7%, respectively. The guideline group on localized prostate cancer of the American Urological Association 5 and Adolfsson et al. 4 weighted published disease-speci®c survival data for deferred treatment at 10 y in two different ways and found it to be 86% and 84%, respectively. The difference between the outcome of deferred treatment, radical prostatectomy and irradiation was small. All three studies are based on the same literature and are subject to the same biases as direct comparisons of the individual studies. The biases that were obvious in the literature such as varying proportions of grade 3 tumors, stage migration and a mixture of prevalent and incident cases were accounted for in the compilation by Adolfsson et al. 4 Also, the number of studies than can be used for compiling data for deferred treatment of localized prostate cancer are limited which compromises the precision of the data. 4, 5 Therefore, the outcome data in these studies can probably not be used for direct comparisons between treatments.
Noncurative management in population-based series
A number of studies of noncurative treatment of men with localized prostate cancer have sprung out of data from various cancer registries.
Data from the Surveillance, Epidemiology and End Results program in the United States has been used in a recent study in which the conservative treatment group was de®ned as those patients with localized prostate cancer who were not subjected to either radical surgery or irradiation. 21 The treatment groups were analysed as intended to treat and the disease-speci®c survival at 10 y for patients with grade 1, grade 2 and grade 3 tumors was 93, 77 and 45%, respectively, after noncurative management.
Albertsen et al. 22 analysed 991 men registered with clinically localized prostate cancer in the Connecticut Tumor Registry from 1971±1976. For various reasons only 451 of the 991 registered patients were ®nally evaluable, of which approximately 40% had immediate endocrine treatment. All grades were included. The cumulative mortality from prostate cancer at 15 y in patients with grade 1, grade 2 and grade 3 tumors was 9, 28 and 51%, respectively. The cumulative mortality from other causes was higher than from prostate cancer for men with grade 1 or grade 2 disease. How the large number of patients that were not evaluable would have affected to outcome of the study is impossible to assess. The great strength of this study is that the diagnosis and the tumor grade was reevaluated in all evaluable cases.
Gro È nberg et al. 23 analysed 6514 men with prostate cancer of all grades and stages registered 1971±1987 in the Cancer Registry of Northern Sweden. They calculated relative survival based on overall and expected survival as well as disease-speci®c survival based on the causes of death on the death certi®cates. Both outcomes were approximately 30% 15 y of follow-up, indicating that the registry data on causes of death are relatively correct and appropriate to use in large population-based studies.
Helgesen et al. 24 used the entire Swedish Tumor Registry and analysed 80 901 men registered with a diagnosis of prostate cancer from 1960 through to 1988. Likewise with the aforementioned study, the relative survival at 15 y was approximately 30% with an increasing trend the later the patients were diagnosed.
Common for these two Swedish population-based registry studies is that the mortality from prostate cancer seems to lessen with increasing follow-up time and this was also seen in a registry study of 12 533 men with prostate cancer in Stockholm, Sweden. 25 With few exceptions the precision of grade and stage, if at all evaluated, becomes poor in these registry studies. Also, the precision in determining the exact treatment that has been given to each patients is low and there is often a mixture of varying regimes in the treatment groups if such groups can be de®ned at all. Therefore, the outcome of these studies can not be compared with outcomes from selected treatment series, but merely represents a general outcome for patients with prostate cancer of various categories in different geographical areas with different attitudes to the management of the disease.
Quality of life
This very important outcome for the patient is poorly studied in men with prostate cancer in general and even less is known for patients who are conservatively managed.
Fossa Ê et al. 26 investigated men with prostate cancer in seven different European countries and those on observation had better sexual function and were less bothered from urinary symptoms than those having been subjected to endocrine treatment, radical prostatectomy or irradia-tion. Patients on observation also scored better regarding global quality of life than those on endocrine treatment or irradiation, whereas the patients subjected to radical prostatectomy had the same global quality of life score as those on observation.
Litwin et al. 27 compared men with and without prostate cancer in a cross sectional study and found that prostate cancer patients had more trouble with their sexual and urinary function than the men in the comparison group. The prostate cancer patients were also more bothered by this than the men without prostate cancer. There was no impact on the overall quality of life. Patients on observation scored better both for sexual function and urinary function and bother than patients treated with radical prostatectomy or irradiation.
In a cross-sectional study in Stockholm men with prostate cancer had greater impairment of their sexual function, more urinary and bowel symptoms and were more bothered by their symptoms than age matched men without prostate cancer. 28, 29 These data largely corresponds with those of Litwin et al.
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In the Stockholm study the patients reporting that they had not had any treatment for their prostate cancer had a lower prevalence of sexual dysfunction and symptoms from the urinary tract and the bowel than those who had been subjected to various treatments. 28 They were also less bothered than those who had had treatment. 28 In summary, prostate cancer and its treatment increase the prevalence of sexual dysfunction as well as symptoms from the urinary tract and the bowel. This is accompanied by a signi®cant bother to the patients. If anything, patients on deferred treatment seem to have fewer problems with their sexual, urinary and bowel function and they also seems less bothered by changes in these function. Since none of the three aforementioned studies were randomized, the differences may be due to selection of different categories of patients to the various treatments. As for survival, we need data on quality of life from randomized treatment studies.
Comments
There has been a growing acceptance of deferred treatment as management for patients with clinically localized prostate cancer during the last decades. Actually it has probably always been utilized to a varying extent and for varying reasons not only in the Scandinavian countries. One example of this is the aforementioned pooled analysis where patients from four different countries were included. 18 Today it is more or less accepted, even by the most aggressive surgeons, that patients with lowgrade low-stage prostate cancer with a life expectancy of 10±15 y or less may not bene®t from aggressive treatment but could be offered deferred treatment as an alternative. 30 This acceptance of deferred treatment is based on the understanding that in most studies the disease-speci®c survival is between 85 and 90% at 10 y after the diagnosis and this does not seem to differ greatly from other treatments up to that point of time.
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Deferring treatment for a potentially fatal disease may seem a paradox to both physicians and patients. This treatment option often takes a long time to explain to the patient and it must be the patient who decides about his treatment. Deferring treatment does not mean that the patient is not taken care of. On the contrary, a close follow-up is mandatory to assess progression and symptoms. The impact on the quality of life of the patients from the knowledge of living with a tumor without being treated is not known but anxiety from the situation must also be regraded as a symptom that needs to be treated.
Irrespective of treatment, aggressive or not, there is a proportion of the patients with initially apparently localized prostate cancer, which is not poorly differentiated, who die of prostate cancer before 10 y after diagnosis. These patients probably had micrometastasis that could not be detected at time of the diagnosis. The locally aggressive treatment was therefore not appropriate in these patients. Beyond 10±15 y of follow-up the data are sparse and partly contradicting. It is therefore not possible to any draw ®rm conclusions about the feasibility of deferred treatment for patients with an expected survival after that point of time. Certainly, a proportion of patients with localized prostate cancer may bene®t from a locally aggressive ef®cacious curative treatment in terms of decreased mortality andaor morbidity. Assuming that men who died of prostate cancer beyond 10 y after the diagnosis in the series on deferred treatment did not have micrometastasis at diagnosis, they may have bene®ted from an ef®cacious treatment with respect to survival. Unfortunately, we do not have prognostic markers with which we can differentiate those patients who will die of their prostate cancer from those who will not either in the short term, or in the long term. We can, however, get some help from using comorbidity scales in assessing concomitant disease and possible impact on the longevity of the patient. 31 Even if some authorities in the area of prostate cancer treatment are convinced that radical prostatectomy andaor irradiation are ef®cacious treatments for localized prostate cancer, we do not yet have any solid scienti®c proof of this. Undoubtedly, some very effective treatments with obvious effects do not need randomized studies to prove their value and it may even be unethical to do such studies. For localized prostate cancer, however, this is not the case, and we need to conduct randomized studies to prove ef®cacy from various treatments if we are to adhere to evidence-based medicine. Continuing to subject large numbers of patients to aggressive treatments which may cause morbidity and even mortality, without trying to ®nd proof for their ef®cacy, is de®nitely unethical. Randomized treatment studies are ongoing, the SPCG-4 study in Scandinavia 32 and the PIVOT study in the United States 33 both randomizing deferred treatment and radical prostatectomy. We will, however, have to wait another 5±10 y before we will have any survival data from these studies.
The whole concept of deferring treatment was questioned recently by a study indicating that the longer a man with initially localized prostate cancer lives, the greater is his risk of dying of prostate cancer. 9 In this series, in the interval from 10±15 y 57%, from 15±20 y 71%, and from 20 y and onwards 71% of those that died, died of prostate cancer. 9 Based on this the authors later argue that all patients needs immediate aggressive local therapy. 34 In their study Aus et al. 9 de®ned the study population as those who died with the diagnosis of prostate cancer irrespective of the cause of death during 1988± 1990. The de®ned follow-up time was from diagnosis to time of death. Since the follow-up time varied considerably for included patients this design makes the inclusion period exceptionally long and, in the case of the series from Gothenburg, more than 25 y. This`follow-back' design differs considerably from the conventional prospective design where the inclusion period is often relatively short. With this long inclusion period, the`followback' design, among other things, becomes dependant on nothing in the conditions of the studied disease changing during the inclusion period, such as sensitivity in the diagnosis, intensity of diagnostic efforts, impact of comorbidity etc. We do know that such changes have occurred during the almost three decades which comprise the inclusion period of their study. Moreover, a bias in the study design is that the follow-up time becomes directly related to when the patients were diagnosed. In fact Aus et al. 9 found that a smaller proportion died from prostate cancer among those diagnosed in the 1980s than in the 1970s than in the 1960s. This corresponds to the increase in relative survival over time that has been described. 3, 23, 24 The`follow-up time' in the Gothenburg series 9 is therefore related to the proportion of patients dying from prostate cancer. The`cohort' thereby becomes what Miettinen 35 called a`biased base' in that it has a built in spurious association between the outcome of interest, in this case the proportion who died of prostate cancer, and the`exposure', that is the length of the followup. Moreover, the conclusion on the mortality from prostate cancer beyond 15 y by Aus et al. 9 was based on only 28 patients. The small numbers may compromise the results and misclassi®cation of the causes of death may also have in¯uenced the outcome.
This study design has been severely criticized 36, 37 and simulations comparing the`follow-back' and the conventional design have shown that Aus et al. 9 probably overestimated the mortality from prostate cancer with long follow-up. 23, 38 Moreover, the results from the various registry studies on noncurative treatment for prostate cancer have shown unanimously a decrease in mortality from prostate cancer with long-term follow-up 23±25 adding strong empiric data to the aforementioned theoretical objections to the study by Aus et al. 9 Therefore, the ®ndings of Aus et al.
9 cannot be compared with data from studies with conventional prospective design and inferences about long-term prostate cancer mortality can not be made from their series.
The vast majority of patients in the studies on deferred treatment and noncurative treatment were diagnosed before PSA came into use for detecting prostate cancer. A lead time of perhaps ®ve years or more has probably been introduced by the use of PSA 39±41 and this, as well as other improved diagnostic measures and an increased awareness, may have increased the number of indolent cases that are detected today. It is impossible to assess the how comparable the results of these studies are to today's conditions, but even among those diagnosed with the means available in the late 1970s and early 1980s, only a smaller part died of their prostate cancer before 10 y of follow-up.
Final remarks
As we stand today, the appropriate treatment for men with localized prostate cancer is not clear-cut. It would be as unreasonable to claim that all patients need not be treated initially as to claim that all patients should have a radical prostatectomy. With the knowledge that we have today, which is based largely on uncontrolled data, we are not in a position where we can safely say that any management, radical prostatectomy, radiotherapy or deferred treatment, is better than the other up to 10 y after the diagnosis with respect to any outcome measure. For patients with an expected survival longer than 10± 15 y we have little data to back our recommendations with. Therefore, instead of being evidence-based, treatment recommendations given to today are largely opinion-based. Our patients must be made aware of this and should not only be informed about the possible survival outcome but also about the morbidity which may be the consequence of the various treatments. In the end the patient must decide which treatment he prefers with the background of his own preferences both with respect to survival and quality of life. It is our task as urologists treating men with localized prostate cancer to inform and educate them about their disease and not to present ®rm recommendations until we have proof to back them with. The most effective, if not the only, way to get such proof is through several randomized studies and, if possible, a subsequent meta-analysis of the studies. Such studies are ongoing presently and need to be endorsed in all respects.
